08:03 AM EST, 02/25/2025 (MT Newswires) -- Eupraxia Pharmaceuticals ( EPRX ) rose 15% in U.S. pre-market trading on Tuesday after announcing additional positive clinical data from its Resolve Phase 1b/2a trial.

The ongoing trial, which is evaluating EP-104GI for the treatment of eosinophilic esophagitis, an inflammatory disease of the esophagus, showed that histological scores and symptom scores continue to improve as EP-104GI dose, and area of esophageal coverage, increased.

One cohort showed the greatest symptom relief scores of all cohorts to date at 12 weeks, while another cohort demonstrated the greatest symptom score reduction seen to date at 24 weeks, showing continuously improving symptom relief over that time, a statement noted.

"We are highly encouraged by the fact that EP-104GI has demonstrated strong activity despite only being administered to varying portions of the esophagus to this point in the trial. This suggests that maximizing esophageal coverage with EP-104GI could lead to further improvements in histology and symptoms," said Dr. James Helliwell, chief executive.

Eupraxia intends to further explore the potential treatment effect of EP-104GI at higher dosing levels and over expanded esophageal coverage in the upcoming cohorts.

The company's shares were last seen up US$0.58, to US$4.42, in New York trading.